We have previously reported a replicable association between variants at the PDE4D gene and familial schizophrenia in a Finnish cohort. In order to identify the potential functional mutations underlying these previous findings, we sequenced 1.5 Mb of the PDE4D genomic locus in 20 families (consisting of 96 individuals and 79 independent chromosomes), followed by two stages of genotyping across 6668 individuals from multiple Finnish cohorts for major mental illnesses. We identified 4570 SNPs across the PDE4D gene, with 380 associated to schizophrenia (p ≤ 0.05). Importantly, two of these variants, rs35278 and rs165940, are located at transcription factor-binding sites, and displayed replicable association in the two-stage enlargement of the familial schizophrenia cohort (combined statistics for rs35278 p = 0.0012; OR = 1.18, 95% CI: 1.06-1.32; and rs165940 p = 0.0016; OR = 1.27, 95% CI: 1.13-1.41). Further analysis using additional cohorts and endophenotypes revealed that rs165940 principally associates within the psychosis (p = 0.025, OR = 1.18, 95% CI: 1.07-1.30) and cognitive domains of major mental illnesses (g-score p = 0.044, β = -0.033). Specifically, the cognitive domains represented verbal learning and memory (p = 0.0091, β = -0.044) and verbal working memory (p = 0.0062, β = −0.036). Moreover, expression data from the GTEx database demonstrated that rs165940 significantly correlates with the mRNA expression levels of PDE4D in the cerebellum (p-value = 0.04; m-value = 0.9), demonstrating a potential functional consequence for this variant. Thus, rs165940 represents the most likely functional variant for major mental illness at the PDE4D locus in the Finnish population, increasing risk broadly to psychotic disorders.
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Introduction
The phosphodiesterase subfamily 4 are protein-encoding genes belonging to the cyclic nucleotide phosphodiesterase (PDE) family, that play a key role in many important physiological processes through regulating and mediating of a number of cellular responses to extracellular signals [1] . Members of the mammalian PDE4 subfamily are evolutionary orthologues of the Drosophila learning and memory mutant Dunce [2] . Flies carrying the mutant Dunce display severe learning/memory phenotypes in different learning situations, showing reduced gene activity and deficits in olfactory learning and memory [3] . Although their involvement in human neuropathophysiology is currently unclear, several studies [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] [15] [16] [17] [18] have implicated PDE4s in psychiatric illnesses, particularly PDE4D and PDE4B. In a GWAS study of patient-related treatment response during antipsychotic therapy, three SNPs, in high-linkage disequilibrium (LD), from PDE4D were found to significantly associate with mediating the effects of quetiapine [4] . In acrodysostosis, a rare disorder characterised by intellectual disability, skeletal and neurological abnormalities, five different point mutations within the PDE4D gene have been identified as the genetic cause [5, 6] . Furthermore, in a genome-wide association study of neuroticism, a psychological trait reported to share genetic factors with both major depression and anxiety, found that one SNP in PDE4D associated with higher neuroticism [7] . This observation has been replicated in two additional independent cohorts, but not in two other cohorts [7] . Behavioural studies on PDE4D-deficient mice reveal increased memory performance in the radial arm and water maze tasks, and object recognition tests [8] . These results suggest that long-form PDE4D is important in mediation of memory and hippocampal neurogenesis through cAMP/CREB signalling, with reduced expression of PDE4D in the hippocampus-enhancing memory. Genetic findings have also been noted with the PDE4D homolog PDE4B. With chromosomal translocations [9] , SNP-based haplotypes [10] [11] [12] and genome-wide SNP association [13] were being observed in studies of schizophrenia. Moreover, genome-wide association studies (GWAS) have also identified PDE4B in studies of anxiety [14] .
Earlier studies have revealed that DISC1 interacts with the conserved regulatory UCR2 domain in both PDE4D and PDE4B, suggesting that DISC1 may modulate PDE4 catalytic activity [9] . A recent study identified variants at the PDE4D locus as a potential risk modifier in the DISC1 translocation family, with follow-up analysis of two UK population-based cohorts (Generation Scotland and UK Biobank), finding suggestive association at PDE4D for affective disorders and related traits [17] . In Finland, PDE4D and PDE4B were first identified as associated to schizophrenia in a study that deliberately set out to study known genes of DISC1-binding partners, as the DISC1 network had already been demonstrated to be of genetic importance within this large cohort for familial schizophrenia [19, 20] . In this cohort of 476 families ascertained for schizophrenia, it was observed that haplotypes in both PDE4D (5q11.2-q12.1) and PDE4B (1p31.3) associated with schizophrenia in a replicable manner [18] . For PDE4D, a haplotype comprising the GGACA alleles of SNPs rs13190249, rs1120303, rs921942, rs10805515 and rs10514862, was observed to be significantly overrepresented in affected individuals (p = 0.00084). Moreover, the SNP rs1120303 also showed replicable association (p = 0.021) in this data set [18] .
These associations, already noted in the Finnish families, were based on SNPs designed to tag the haplotypic structure of the genes of interest, and are thus not expected to be the functional mutations but instead only represent surrogate variants. Thus, here we sought to examine in detail PDE4D, which is the gene of the PDE4 subfamily offering the more solid evidence for association to schizophrenia in the Finnish population, in order to identify any variants with potential functional consequences. This utilised a threestage study design that would sequence the genomic locus of PDE4D, and two rounds of genotyping in everincreasing sample numbers from the familial schizophrenia cohort, so that variants of interest can be identified, verified and replicated in an independent, but identically ascertained cohort. This design was chosen as it is expected, based on the level of the prior observations (best p = 0.00084, Tomppo et al. [18] ), that any association with a single variant will not surpass the genome-wide significant threshold of 5.0 × 10
, and thus replication of the findings is of paramount importance. Observations that passed through this three-stage design were then characterised further. We utilised seven other Finnish cohorts representing a range of major mental illness phenotypes, first individually and then jointly, to study the gene's role in psychotic and mood disorders. Furthermore, we studied neuropsychological endophenotype data that have been collected within the familial cohorts used here. See supplementary Fig. 1 for an illustration of the study workflow.
Materials and methods

Samples
The samples studied came from multiple Finnish cohorts collected to study major psychiatric disorders, using a number of different study designs, including familial, twin and population-based cohorts (Supplementary Table 1) , and phenotypes, including multiple diagnoses alongside neuropsychological endophenotypes. In total, this joint cohort consisted of 7024 individuals for which 6668 have been genotyped, including 1909 psychiatrically healthy control samples. The individual cohorts have been described in great detail previously [21] [22] [23] [24] [25] [26] , and are briefly described, along with their abbreviations, in the Supplementary Materials. These samples include two familial cohorts, for schizophrenia (FSZ, n = 2818) and bipolar disorder (BPD, n = 650), a sample of twin pairs concordant and discordant for schizophrenia (Twin, n = 303), three population cohorts ascertained for different aspects of psychotic disorders (FEP, n = 125; MMPN, n = 449; HUPC, n = 383), a population cohort for anxiety disorders (Anx, n = 823) and a sample of population controls (Controls, n = 1117).
In order to maximise the analytical potential of the cohorts studied here, we combined all, except the 207 anxiety cases, into a joint analysis of two broad major mental illness-related phenotypes. These dichotomous traits were derived from the diagnoses of each affected individual, where we could classify them as either having a psychotic disorder and/or mood disorder. The psychotic disorder phenotype included those individuals with any of the following diagnoses: schizophrenia, schizoaffective disorder, schizophrenia spectrum disorders, schizophreniform, psychotic disorders and bipolar disorders and major depression only with a specification of including psychotic features. The mood disorder phenotype included individuals with the following phenotypes: bipolar disorder type I or type II, major depression, schizoaffective disorder and psychotic disorders where major depressive or manic episodes had been present. In total, there were 1896 people categorised with a psychotic disorder, and 1227 with a mood disorder, 628 individuals could be categorised as cases under both phenotypes.
Sequencing, genotyping and SNP selection
The data to be investigated in this research have been generated through a three-stage replication study design to increase our power to detect true positives while lowering the amount of false-positive findings, compared with using an overly conservative Bonferroni correction [27] . Firstly, to identify variants in the familial schizophrenia cohort, we sequenced the 1.5 Mb genomic region of the PDE4D gene (chr5:58254866-59793925; sequencing read depth = 80.53; mean coverage = 86.43) in a subset of 20 families using Illumia HiSeq2000, HiSeq1500 sequencing platform and Nimblegen SeqCap EZ 6 Mb as the target enrichment kit. Sequencing data were analysed using an in-housedeveloped SAMtools-based bioinformatics pipeline (VCP) for quality control, short-read alignment (using Burrows-Wheeler Aligner), duplicate removal and variant identification (with pileup) followed by variant annotation [28] . The 20 families comprised 96 individuals (affected = 42; liability class (LC) LC1 = 28; LC2 = 12; LC3 = 2; LCs explained below), with 79 independent chromosomes for variant identification and segregation analysis. Identified variants were filtered by VCP according to the following: any variant call with a quality ratio of more than 0.8 was considered as a reference call and was filtered out. Calls with a quality ratio between 0.2 and 0.8 were considered to be heterozygous and calls below 0.2 to be homozygous variant calls. The filtered variants were aligned with bioinformatic predictions of function, with the major focus on their location in exonic and regulatory sites, as predicted by UCSC genome browser build 19 (Supplementary  Table 2 ). SNPs were selected for genotyping based on the following criteria. Firstly, SNPs display any evidence of LD|Linkage association in this small cohort (p ≤ 0.05), and locate in predicted functional areas: five exonic, one CpG and eight TFBS. In addition, SNPs were selected that showed Linkage p-value ≤ 0.05, and also had two other lines of evidence from TFBS, a score in the UCSC Brain Methylation track, or tentative association to an endophenotype for schizophrenia (social anhedonia) in our prior studies in a birth cohort from Northern Finland [29] (Supplementary Table 2 ). Of the 19 SNPs selected, seven dropped out due to the inability to be fitted into a multiplex for Sequenom genotyping. Genotyping was performed using a Sequenom MassArray platform [30] according to the manufacturer's recommendations. Several quality control measures were applied across the genotyping stages, including high marker success rates (>95%), HWE p-value > 0.01, optimal primer usage without leftover residues and no background signals in water. Stage-one (S1) genotyping was performed in a sub-cohort of the schizophrenia families (n = 1122 individuals in 301 families) alongside population-based controls (n = 323 individuals), in order to verify both the variant's existence, if the variation was novel to this sequencing data, and independent association (p ≤ 0.05) to schizophrenia. Those variants that were both verified and associated in this larger cohort were further taken for stage-two (S2) genotyping, which included the rest of the schizophrenia cohort (n = 1696), alongside the other major mental illness cohorts (total n = 2733) and additional population-based controls (n = 794). The variant rs39672 displayed significant inconsistencies in its minor allele frequency between the controls of S1 and S2 (MAF S1 = 0.24; MAF S2 = 0.39: p = 1.71 × 10
; Supplementary Table 2 ) and was thus discarded, as there were no significant geographical or gender differences between these two stages that could reasonably account for such a difference.
Association analysis
Association analysis within the individual cohorts was carried out either using Pseudomarker [31] (family-based or twin cohorts (FSZ, BPD, twin, psychotic disorder and mood disorder)) or PLINK [32] (population-based cohorts (MMPN, HUPC, FEP and Anx)). Pseudomarker analyses test was conducted for single-marker (two-point) association and linkage. Furthermore, Pseudomarker can utilise data of differing epidemiological design, helping us to combine familial studies with population controls, alongside singleton cases from other cohorts. It can handle missing data, even when the genotypes of the parents are unknown. The 'association given linkage' (LD|Linkage) option of the programme was used to identify association for the SNPs with the diagnosis (p ≤ 0.05), using the three main genetic models (dominant, recessive and additive) assuming incomplete penetrance. LD|Linkage corrects for the effect of any linkage within the families that may influence the observed association. The specific penetrance of alleles identified as associated in these cohorts was later calculated using the formula proposed by Wang et al. [33] . PLINK was used to analyse population-based cohorts, where the family structure was not known; however, these cohorts may contain some related individuals. The options -model and -perm produced the p-values, using permutation tests to generate significance levels empirically.
In the family cohorts for schizophrenia and bipolar disorder, different liability classes (LC) of the diagnoses were used in the analyses. The schizophrenia cohort liability classes (LCs) constitute of LC1, where individuals were diagnosed for schizophrenia only, LC2 added those individuals affected with schizoaffective disorder, LC3 added individuals with schizophrenia spectrum disorder and LC4 added individuals with bipolar disorder or major depressive disorder. In the bipolar cohort, the liability classes (LC) are LC1 bipolar disorder type I, LC2 adds schizoaffective disorder, bipolar type, LC3 adds bipolar disorder type II and LC4 adds recurrent major depressive disorder. All other cohorts only used the single diagnostic criteria, for which the cohort was ascertained (Supplementary Tables 3-6 ). In the sequencing stage, association analysis was only performed using the broadest liability class possible, LC4, to maximise the number of cases (n = 42) versus unaffected family members (n = 54).
Endophenotypes and QTDT
A total of 919 subjects from the schizophrenia (n = 811) and bipolar (n = 108) familial cohorts have been administered a comprehensive neuropsychological test battery, consisting of a series of well-validated, and internationally used, means to measure cognitive ability. From this test battery, a total of 14 quantitative neuropsychological variables with previous evidence of potential to use as an endophenotype were available [34] [35] [36] [37] [38] [39] . These endophenotypes that are included were verbal learning and memory derived from the immediate, short-delay and long-delay recall tasks from the California Learning Test (CVLT) battery [40] ; Verbal skills from the Similarities and Vocabulary subtests of the Wechsler Adult Intelligence ScaleRevised (WAIS-R) battery [41] ; Visual working memory from the Visual span forward and backward and Verbal working memory from the Digit span forward and backward tests from the Wechsler Memory Scale-Revised battery (WMS-R) [42] ; Information Processing from the Stroop colour task and colour-word task [43] and the Trail Making Test, parts A and B [44] ; and the Digit Symbol subtest from the Wechsler Adult Intelligence Scale-Revised (WAIS-R) battery [41] . Most of the endophenotypes were normally distributed; however, the Trail Making and Stroop tasks were transformed, so that the scores represented speed (number of items/performance time). As the neuropsychological endophenotypes are related, they could be grouped into five first-order factors using factor analysis (Table 2) , and a second-order general ability factor (g-factor) based upon previous results [45] for cognition-related traits. The factor analysis was performed with Mplus 7.3. We used confirmatory factor analysis with a maximum likelihood estimator and with robust standard errors, using family as a cluster and affected versus not affected as a grouping variable. The fit of the model was acceptable (CFI = 0.932; RMSEA = 0.085).
The programme QTDT [46] was used for the analysis of the endophenotypes, factors and g-factor. This method relies on variance components testing for any transmission distortion within the families. These 919 individuals contain 395 affected individuals, under the broadest diagnostic classifications for the two cohorts, and 524 unaffected relatives. Gender, age and the broadest classification of affection (LC4) in both the schizophrenia and bipolar family cohorts were treated as covariates during the analysis. The orthogonal model (-ao) together with 1,00,000 permutations generated the empirical p-values. The orthogonal model allows for families of any size with or without parental genotypes, whereas permutation provides robust findings in the presence of stratification, providing an empirical p-value for the observed difference in the trait. The strength for this analysis comes from the consistency of the findings, with regard to the related endophenotypes and factors. Due to the relatedness of these traits, Bonferroni correction for multiple testing would be overly conservative; thus, we report the uncorrected empirical p-values and highlight those that would survive multiple test correction for 14 endophenotypes (p = 0.00357), five factors (p = 0.010) and the single overall g-factor (p = 0.05). Multiple regression using R software (with age, gender, affection status and family as covariates) was used to determine directionality of significant correlations between SNPs and endophenotypes through derivation of beta-estimates (β) ( Supplementary  Fig. 2a, b) .
Linkage-disequilibrium (LD) analysis
In order to investigate the relatedness between our identified variants, and between our observations and those of the previous study [18] , the identified variants from this study were mapped onto the previously determined LD haplotypes of PDE4D using the Haploview program [47] . For the latter, the D′ haplotype structure of the SNPs previously studied was manually enforced onto these data with Hedrick's Multiallelic D′ [48] determined between the haplotype and the two identified SNPs. However, for the correlation between our two identified SNPs the r 2 LD was calculated.
Results
The sequencing of PDE4D in 20 families identified 4570 variants, of which 380 variants associated with a broad schizophrenia diagnosis (p ≤ 0.05). Using multiple levels of information, 12 variants were genotyped in the first stage (S1), of which four were both verified and remained significant in their association to schizophrenia in this enlarged cohort, and were therefore taken forward for replication in the second genotyping stage (S2). Two potential regulatory SNPs were identified to significantly replicate in their association to schizophrenia (Table 1 , Fig. 1 ; Supplementary Table 4 ), and were thus studied within the combined familial schizophrenia cohort: rs35278 (LC3 additive; p = 0.0012; OR = 1.18, ± 95% CI 1.06-1.32) and rs165940 (LC3 additive; p = 0.0016; OR = 1.27, ± 95% CI: 1.13-1.41). These two SNPs are in relatively high-linkage disequilibrium, r 2 = 0.66. No gender or geographical-based differences were observed in our analyses.
Association analysis in the other major mental illness cohorts revealed that rs35278 significantly associates within the familial bipolar disorder cohort with broadening liability classes, but most significantly with LC2, bipolar type I and schizoaffective, bipolar type (LC2 additive p = 0.032; OR = 1.27, ± 95% CI 1.04-1.56) (Supplementary Table 5 ). We observe that both of our variants are partially penetrant in these ascertained familial cohorts, with rs35278 displaying low (FSZ = 0.15, BPD = 0.21), and rs165940 (FSZ = 0.36, BPD = 0.50) displaying moderate penetrance Table 3 Fig . 1 Odds ratios, and their respective 95% confidence intervals, for the two SNPs across the cohorts studied and the joint analysis. All plots represent the observations for the additive genetic model. For the schizophrenia family cohort only, the finding for liability class 3 is shown, while for the familial bipolar disorder cohort, only liability class 2 is shown in these families for the respective LCs, providing the best evidence of association. Neither SNP associated within the other individual cohorts (Supplementary Table 6 ); however, the joint cohort analysis highlights the involvement of both SNPs with a broad diagnosis of any psychotic disorder (rs35278 additive p = 0.023, OR = 1.13, ± 95% CI: 1.02-1.24; rs165940 additive p = 0.025, OR = 1.18, ± 95% CI: 1.07-1.30) (Supplementary Table 6 ). Follow-up analysis of these two SNPs using quantitative neuropsychological endophenotypes demonstrated that both SNPs provide evidence for association to an overall measure representing a g-score (rs35278 p = 0.043, β = -0.025; rs165940 p = 0.044, β = −0.033) ( Table 2 ). When investigating the sub-domains of cognition through use of factors, only rs165940 continued to display association levels that would survive Bonferroni correction for the number of factors tested. The minor allele, T, significantly associates with decreased performance in the factors representing verbal working memory (p = 0.0062, β = −0.036), and verbal learning and memory (p = 0.0091, β = −0.044) ( Table 2 ). Analysis of the individual endophenotypes shows that under the factors verbal learning and memory, the T allele associates with decreased scores on the immediate recall task (p = 0.0032, β = −0.65) ( Table 2 ). Since the SNPs associate with diagnosis, which was used as a covariate in these analyses, we also studied these endophenotypes without affection status as a covariate. No significant association survived Bonferroni correction in these tests (Supplementary Table 7 ).
Since both the SNPs have a potential regulatory function based on their locations being predicted at transcription factor-binding sites, we checked the extent of their functional consequences using tissue-specific expression quantitative trait loci (eQTL) from the GTEx portal [49] . Only rs165940 showed significant association with expression changes in PDE4D within the brain, specifically the cerebellum region (p-value = 0.04, m-value = 0.9) (Supplementary Fig. 3 ). Significant modulation of expression of PDE4D by rs165940 is also detected in the oesophagus, heart and prostate tissues; the meta-analysis over all tissues gives a p-value of 0.00000017.
Discussion
Through the use of a three-stage sequencing and genotyping approach to identify, validate and replicate potential functional mutations at the PDE4D gene, we have identified two SNPs of principal interest to the aetiology of major mental illness in Finland. Both SNPs displayed replicable association in the familial schizophrenia cohort, are located in predicted transcription factor-binding sites and are in relatively high LD with each other (r 2 = 0.66). Significant association with these SNPs was observed across liability classes and genetic models; the relevant phenotype was further refined using additional cohorts (see below), while the fact that all genetic models displayed associations suggests that the additive model is the most likely [50] . The [14] , the number of factors [5] or g-factor [1] tested are in bold and italics issue of LD makes it difficult to discern which of the two SNPs is the most likely functional mutation. Under the assumption that both SNPs are tagging the same true effect, then the higher allele frequency of rs35278 gives it a greater power for detection in the association analyses; thus, use of additional cohorts for major mental illness highlighted only rs35278 as also associating with bipolar disorder. However, when the cohorts were combined to study psychotic and mood disorders as a whole, both SNPs again displayed significant association, to psychotic disorders. The minor alleles of both SNPs (rs35278 G allele, rs165940 T allele) were significantly enriched in the disorders. The use of neuropsychological endophenotypes indicates that both SNPs display significant association to an overall measure of cognition, while analysis of factors and individual endophenotypes shows both SNPs displaying association, but with only T allele of rs165940 being significantly so, to reduced scores in the factors representing verbal learning and memory, and verbal working memory and the endophenotype immediate recall. Through the analysis of the functional consequences of these SNPs on the gene expression levels of PDE4D within the GTEx database, we gained extra insight that could help to specifically separate these two variants, with only rs165940 significantly associating with gene expression levels in PDE4D. This evidence from the GTEx database highlights rs165940 as the primary candidate for the functional mutation at this locus; however, we cannot rule out the functional effect also for rs35278. These expression-level differences could be identified not only in the brain and the cerebellum, but also other tissues, such as the oesophagus, heart and prostate. While these expression changes indicate the potential functional consequence of rs165940 on PDE4D, these are not necessary in tissues of direct relevance to the phenotypes being studied. Although there is growing evidence for the involvement of the cerebellum in major mental illness [51] [52] [53] [54] [55] , our identification of association to learning and memory would more traditionally be associated with functions of the hippocampus. It can be noted that the eQTL status of rs165940 on PDE4D in the hippocampus is approaching significance, but the GTEx data size is smaller compared with that of the cerebellum (hippocampus n = 111, cerebellum n = 154; Supplementary Fig. 3 ). As sample sizes increase, this may become truly significant. Since this study is an extension of one that had previously implicated PDE4D in this familial cohort for schizophrenia, we determined whether our current findings are in concordance with our prior observations [18] . Thus, we mapped our SNPs onto the SNPs and haplotypes of PDE4D previously used to study the common haplotypic background of the gene. This prior work based its haplotypic analysis around D′ LD. Both the SNPs are within some degree of D′ LD (rs35278 = 0.43, rs165940 = 0.47) with the previously associating haplotype (Supplementary Fig. 4a, b) , which, although modest, suggests some relationship between these observations. However, these SNPs are not in any r 2 LD with rs1120303, the prior SNP association of Tomppo et al. [18] (rs35278 = 0.10; rs165940 = 0.05).
It is important to note that the approach taken in this study design is not only a strength, as it enables us to directly replicate our findings using an identically ascertained cohort, but also a weakness. The initial sequencing step only used 96 related individuals, consisting of 79 independent chromosomes, meaning that the full scope of variation at the PDE4D locus within these families has not been determined, with rarer mutations (MAF < 0.01) in these families likely to have been missed. However, our prior evidence at PDE4D implied that any mutation would be common (frequency > 5%), as the associating haplotype allele had a frequency in affected individuals from this cohort of 0.40 (control frequency = 0.28), and the SNP which showed some association had a minor allele frequency (MAF) of 0.13 (control MAF = 0.19). The high frequency of rs165940, not just in the cohorts studied here, Finnish familial schizophrenia cases (MAF = 0.34, 78% of FSZ families carry one or more copies of the risk T allele), and psychiatrically healthy controls (MAF = 0.29), but also in population genomic cohorts [56] for the Finnish population (MAF = 0.32) and the non-Finnish Europeans (MAF = 0.28), does in turn suggest that these variants could have been detected by large-scale genome-wide approaches, and yet, to date, this is not the case. While current genetic evidence identified in familial cohorts for schizophrenia is markedly different from those identified through population-based study designs, it is worth noting that the latest consortia-based genome-wide association study has identified PDE4B in its study of schizophrenia [13] . This is part of the same subfamily as PDE4D, and was also identified as associating to schizophrenia in the Finnish familial schizophrenia cohort used here. The high frequency of the PDE4D SNPs, combined with their low odds ratio/effect size, would imply that with further increases in sample size, PDE4D could also be identified through population-based approaches. Whereas our three-stage study design has allowed us to identify significant variants through replication, rather than being dependent on reaching the genomewide significance threshold of 5.0 × 10 −8 .
Our findings strongly support the role of PDE4D in psychiatric disorders, with replicable association in familial schizophrenia in Finland. Further characterisation suggested that it plays a role in both psychosis and cognitive endophenotypes of major mental illnesses. In particular, we demonstrate that the SNP rs165940, through its association pattern and being identified as an eQTL for the PDE4D gene, makes it the principal variant of interest for being the functional mutation at this locus. The variant rs165940 is located in a transcription factor-binding site positioned in an intron of the longer isoforms of PDE4D, but upstream of two short isoforms. From the data used here, it cannot be discerned if there are specific PDE4D transcripts being altered by this locus, yet given its location, it would be expected that any eQTL effect this SNP has on PDE4D may well be isoform specific. Thus, further studies into the functional consequences of this variant are essential.
